Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients

Status Completed

Clinical Trial Summary

i. Project Background Patients with advanced lung cancer have a high symptom burden and low quality of life. Early palliative care improves patient outcomes in newly diagnosed advanced lung cancer patients, but previously tested models are not feasible for widespread adoption. Hence, the aim of this study is to pilot a more sustainable nurse-led intervention - Enhancing Quality of life in Patients (EQUIP).

ii. Hypothesis / Aim The aims of this study are three-fold. Firstly, the investigators aim to determine the feasibility and acceptability of the EQUIP intervention itself. Secondly, the investigators aim to obtain a tentative estimate of efficacy of the EQUIP intervention. Thirdly, the investigators aim to determine the data completion rate of patient reported outcome measures in the context of the EQUIP trial.

iii. Methods Patients with newly diagnosed stage 3 or stage 4 lung cancer will be recruited and randomized to the EQUIP intervention or usual care (control) group. Patients randomized to the EQUIP intervention group will receive four face-to-face sessions with a palliative care nurse. The content of these educational sessions will equip patients with the knowledge and skills to manage the three commonest symptoms of fatigue, breathlessness and anxiety.

All participants will complete the Functional Assessment of Cancer Therapy - Lung (FACT-L), the Hospital Anxiety and Depression Scale (HADS) and the stigma subscale at four time points: baseline, 4, 8 and 12 weeks after recruitment. Measures of healthcare use will also be recorded. Additionally, participants in the intervention group will complete a feedback survey after each intervention session.

A total sample of 60 patients (30 in each arm) will be recruited.

Clinical Significance

If successful, this study will lead to a larger scale phase III trial which tests various components of the EQUIP intervention, in order to develop a sustainable and effective model for the provision of palliative care to advanced lung cancer patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02801734
Study type	Interventional
Source	National Cancer Centre, Singapore
Contact
Status	Completed
Phase	N/A
Start date	August 1, 2016
Completion date	December 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04575831` - Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)	N/A
Completed	`NCT04069494` - Descriptors and Predictors of Burden and Information Needs
Terminated	`NCT03330834` - CAR-T Cell Immunotherapy for Advanced Lung Cancer	Phase 1
Withdrawn	`NCT03004105` - MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)	Phase 2
Withdrawn	`NCT03501056` - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer	Phase 2
Not yet recruiting	`NCT05279521` - The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.	N/A
Terminated	`NCT02768337` - Cambridge Brain Mets Trial 1	Phase 1/Phase 2
Completed	`NCT04672369` - A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC	Phase 1
Recruiting	`NCT03751592` - Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT05431569` - A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer	Phase 2
Not yet recruiting	`NCT06456138` - Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC	Phase 1/Phase 2
Recruiting	`NCT06228209` - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer	N/A
Completed	`NCT04672356` - A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer	Phase 1
Active, not recruiting	`NCT04670445` - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer	N/A
Not yet recruiting	`NCT06107894` - TIL Therapy for Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06183762` - A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Recruiting	`NCT05664971` - JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT05815862` - Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer	Phase 2
Recruiting	`NCT05805956` - IMM2902 in Patients With Advanced Solid Tumors Expressing HER2	Phase 1/Phase 2
Recruiting	`NCT06106152` - WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer — EQUIP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms